177A

Kohjin Bio Co., Ltd.

コージンバイオ株式会社
Pharmaceutical
Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreservation solutions; cell dissociation agents; adoptCell-NK kits, and bag and other materials. In addition, the company offers microbial mediums for clinical microbiology culture mediums, microbiology culture medium for food and environment, antimicrobial resistance test kits, and staining kits for microbiology; immunochromatographic assay kit; I-block series; and human blood, serum, and plasma. Further, it engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. Kohjin Bio Co., Ltd. was incorporated in 1981 and is headquartered in Sakado, Japan.
← Companies
Price
¥1,007
Market Cap
¥5.1B
Ent. Value
¥4.0B
Net Cash
¥1.1B
Shares Out.
5.1M
P / E
6.4×
EV / EBIT
4.1×
P / Book
0.89×
P / NCAV
2.89×
Div. Yield
2.38%
Financials
Metric FY 2024
EDINET ↗
FY 2023
EDINET ↗
Net Sales ¥5.2B ¥4.8B
Cost of Sales ¥2.8B ¥2.9B
Gross Profit ¥2.4B ¥1.9B
SG&A ¥1.4B ¥1.3B
Operating Income ¥991M ¥597M
Non-Operating Income ¥118M ¥94M
Dividend Income ¥0M ¥0M
Interest Income ¥2M ¥1M
Non-Operating Expenses ¥44M ¥55M
Interest Expense ¥30M ¥23M
Ordinary Income ¥1.1B ¥636M
Pre-tax Income ¥1.0B ¥636M
Income Taxes ¥221M ¥251M
Current Tax ¥247M ¥276M
Deferred Tax ¥-26M ¥-25M
Net Income (owners) ¥795M ¥385M
Comprehensive Income ¥843M ¥404M
EBITDA ¥1.4B ¥896M
EPS ¥157.57 ¥92.43
Shares Outstanding 5.1M 4.2M
Shares Issued (total) 5.1M 4.2M